Monoclonal Antibodies against Stathmin Combined with Paclitaxel Inhibit Growth of QG-56 Human Lung Carcinoma Cells

Lung cancer is one of the most harmful malignant tumors to human health and life, and its incidence is increasing every year, and ranking the first in large and medium-sized cities in the incidence of malignant tumors. 2/3 of patients are in advanced stage when diagnosed as lung cancer and lose the opportunity of surgical treatment. Chemotherapy is primarily used for the treatment of advanced lung cancer. Although new anti-cancer drugs and chemotherapies have been introduced, the outcomes for some patient are not satisfactory, and patients are becoming less tolerated as the chemotherapy extends. Therefore, targeted therapy of lung cancer becomes the research hotspot in recent years. Recently, erlotinib and gefitinib are widely used in lung cancer therapy, but both of which are only effective for specific pathological situations and patients, the outcomes for rest of the patients are still not satisfactory (Zhang et al., 2005; Zhou et al., 2008). Stathmin is a newly discovered target for gene therapy in cancer in recent years. Stathmin is a soluble protein which plays a very important role during cell proliferation and differentiation, 20kD, consisting of 149 amino acid. Studies of cell signal transduction shows that a variety of cytokines, protein product of oncogenes and tumor suppressor genes from inside and outside of cells could